ARCHIVES

FDA Approves Ribavirin Phase 102 Trials

This article is from The Cancer Letter archive.

Vol. 13 No. 42 | October 30, 1987

Download PDF Visit The Full Archive

Related Articles

Post Reporter Responds To Criticism Of Cancer Series

January 1, 1982

Genomic Health Presents Meta-Analyses of Oncotype DX

January 28, 2011

Novel Antifungal Agent Highly Active Against Esophageal Candidiasis

October 31, 2003

In Brief: Centers Survey Generates Only 56 Responses GAO to Report On NCI’s Dissemination Efforts

January 22, 1988

NCAB Gives Life To Three CBCCP Contractors Marked For Termination; Compromise “Reasonable” – DeVita

May 30, 1980

NCI Awards $6.7 Million For Breast Cancer Research.

September 8, 2000